This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Hepatitis C Immune Globulin (Human)
Description: Civacir is a human polyclonal antibody product that contains antibodies to the hepatitis C virus (HCV).
Deal Structure: Nabi has an agreement with Chiron Corporation granting Nabi an exclusive supply agreement for four vaccines, including for hepatitis C. Univax had announced the collaboration with Chiron on the same day the merger between Univax and Nabi was announced in 1995. The agreement may apply to the development of the next generation of Civacir. Chiron was acquired by Novartis in April 2006.
In June 2006, Nabi Biopharmaceuticals announced that it secured an agreement with Kedrion S.p.A., a global biopharmaceutical company, located in Lucca, Italy. Under the terms of the agreement, Nabi Biopharmaceuticals and Kedrion will pursue a common strategy to develop and commercialize Civacir in Europe and the U.S., with Kedrion being Nabi Biopharmaceuticals' exclusive licensee to commercialize Civacir in Europe. In addition to milestone and royalty payments to be paid to Nabi Biopharmaceuticals, Kedrion will assume development costs for the product candidate in both Europe and the U.S. through at...See full deal structure in Biomedtracker
Partners: Novartis AG Kedrion S.p.A.
Additional information available to subscribers only: